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Background: Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality.
Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the
risk of stroke. In practice, many patients with AF do not receive the appropriate antithrombotic therapy and are left
either unprotected or inadequately protected against stroke. The purpose of the Global Anticoagulant Registry in
the FIELD (GARFIELD) is to determine the real-life management and outcomes of patients newly diagnosed with
non-valvular AF.
Methods/design: GARFIELD is an observational, international registry of newly diagnosed AF patients with at least
one additional investigator-defined risk factor for stroke. The aim is to enrol 55,000 patients at more than 1000
centres in 50 countries worldwide. Enrolment will take place in five independent, sequential, prospective cohorts;
the first cohort includes a retrospective validation cohort. Each cohort will be followed up for 2 years. The UK
stands to be a significant contributor to GARFIELD, aiming to enrol 4,582 patients, and reflecting the care
environment in which patients with AF are managed. The UK protocol will also focus on better understanding the
validity of the two main stroke risk scores (CHADS2 and CHA2DS2VASC) and the HAS-BLED bleeding risk score, in the
context of a diverse patient population.
Discussion: The GARFIELD registry will describe how therapeutic strategies, patient care, and clinical outcomes
evolve over time. This study will provide UK-specific comprehensive data that will allow a range of evaluations both
at a national level and in relation to global data and contribute to a better understanding of AF management in
the UK.
Trial registration: ClinicalTrial.gov: NCT01090362
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Atrial fibrillation (AF) is the most common clinically sig-
nificant arrhythmia in the adult population; it is an inde-
pendent risk factor for stroke and mortality. People with
AF have a fivefold increased risk of stroke and a twofold
increased risk of death [1]. Prevalence of AF increases
throughout life, affecting less than 1% of individuals* Correspondence: d.a.fitzmaurice@bham.ac.uk
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reproduction in any medium, provided the orunder 60 years, approximately 4% of individuals over 60
years, and up to 10% of over those aged 80 years [2,3].
The estimated diagnosed prevalence of AF in the UK
is around 1.4% [4,5], and more than 46,000 new cases of
AF are diagnosed every year [6]. About 15% of all
strokes are caused by AF, and 12,500 strokes each year
in England are thought to be directly attributable to AF
[7]. Furthermore, AF-related strokes are more serious:
they are more likely to be fatal than strokes in patients
without this arrhythmia; among patients who survive,
these strokes cause more disability with less likelihood
of independent recovery [8]. For example, findings fromral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased 1.84-fold in strokes in people with AF compared
to those in sinus rhythm, and recurrence is more fre-
quent [9]. The Copenhagen stroke study found that pa-
tients with AF require longer hospital stays (50 days
versus 40 days, P < 0.001) and a lower discharge rate to
their own homes (odds ratio 1.7; 95% confidence interval
[CI] 0.44 to 0.85) with poorer neurological and func-
tional outcomes [8]. Further, data from the European
community stroke project show that AF increased by
50% the probability of remaining disabled (odds ratio
1.43; 95% CI 1.13 to 1.80) or handicapped (odds ratio
1.51; 95% CI 1.13 to 2.02) [10].
Management of AF requires either a rate-control strat-
egy to slow the ventricular rate or a rhythm-control
strategy in an attempt to maintain sinus rhythm. Regard-
less of whether the rate-control or the rhythm-control
strategy is pursued, antithrombotic therapy for preven-
tion of stroke and thromboembolism is a fundamental
management tool.
Oral anticoagulants are effective in the reduction of
stroke and thrombolytic events among patients with AF.
Vitamin K antagonists (VKAs) are the most widely used
anticoagulants and adjusted-dose warfarin has been shown
to reduce the risk of stroke by approximately 60% in pa-
tients with AF [9]. However, in practice the use of VKAs is
not universal [10]. As a result, only about one-half of the
patients who should receive antithrombotic therapy to
prevent thromboembolic stroke actually receive it [11].
Risk stratification is important when considering
anticoagulation, as the risk of stroke in AF patients is
dependent on clinical predictors [12]. A recent stroke
risk stratification scheme, CHA2DS2-VASc (Cardiac fail-
ure, Hypertension, Age ≥75 [Doubled], Diabetes, Stroke
[Doubled] – Vascular disease, Age 65–74 and Sex cat-
egory [Female]), has been proposed as an alternative to
CHADS2 [13]. CHA2DS2-VASc adds further variables to
CHADS2 – age 65–74, female sex, and vascular disease,
and thromboembolism in addition to stroke/ transient
ischaemic attack (TIA).
Anticoagulant therapy carries a risk of bleeding, and
major bleeding such as intracranial bleeds can be cata-
strophic. Bleeding risk-stratification schemes assess the
risk of major bleeding for patients on anticoagulation to
help determine the risk–benefit balance in AF. A novel
bleeding risk score – HAS-BLED (Hypertension, Abnor-
mal renal/liver function [1 point each], Stroke, Bleeding
history or predisposition, Labile international normalised
ratio [INR], Elderly [>65], Drugs/alcohol concomitantly
[1 point each]) [14] – is gaining recognition internation-
ally [12] and in the UK, and could potentially improve
assessment of bleeding risk in patients with AF.
In 2006 the National Institute for Health and Clinical Ex-
cellence (NICE) published guidelines for the managementof AF, with priorities on identification and diagnosis of AF,
treatment of AF, and provision of antithrombotic therapy
[15]. One of the key recommendations of the guidelines is
a formal assessment of the risk of thromboembolism using
a stroke risk stratification and thromboprophylaxis algo-
rithm (Figure 1). The guideline proposes routine anticoa-
gulation with warfarin for patients at high risk of stroke,
and aspirin for those at low risk of stroke.
The prevalence of AF in the UK is increasing, probably
due to the ageing population and improved survival
from conditions predisposing to AF, including, for ex-
ample, myocardial infarction. A large population-based
study of the epidemiology and treatment of AF in the
UK found prevalence of diagnosed AF rose steadily
(0.84% in men in 1994 compared with 1.49% in 2003,
compared with 0.83% and 1.29%, respectively, in women)
[4]. The number and proportion of AF patients in the
UK prescribed antithrombotic therapy has progressively
increased over time [4,16]. An analysis of national data
from 1994 to 2003 found under one-half of all AF pa-
tients received any antithrombotic treatment in 1994 but
around 80% received some sort of stroke prevention in
2003 [4]. Also, treatment of AF with oral anticoagulants
more than doubled from 1994 to 2003 in men (25% to
53%) and has increased significantly women (32% to
40%) [4]. However, the use of anticoagulants remains in-
appropriate [4,17] and the NICE 2006 costing report es-
timated that 46% of patients who should be on warfarin
are not receiving it [18]. There is also evidence to sug-
gest underuse of anticoagulation in the elderly; for ex-
ample, in one study elderly patients (age >85 years) were
less likely to initiate warfarin (relative rate 0.16, 95% CI
0.15 to 0.18) and more likely to start aspirin (relative
rate 1.66, 95% CI 1.47 to 1.88) compared with patients
aged 40–64 years [17].
Much of the UK evidence is based on retrospective
cross-sectional studies and was derived from prevalence
data. As such, there is limited evidence on persistence of
treatment with antithrombotic therapy and it has been
indicated that only 60% of patients prescribed warfarin
continue for at least 2 years [17]. Also, much of the
available evidence relates to AF management prior to
the publication of the NICE guidelines in 2006. It is not
clear how well clinicians adhere to these guidelines and
what impact this has had. There is an absence of con-
temporary longitudinal data on the clinical management
of AF in the UK, including the key therapeutic area of
antithrombotic therapy, persistence of therapy, and re-
lated clinical outcomes.
Importance of GARFIELD UK
The Global Anticoagulant Registry in the FIELD (GAR-
FIELD) is an observational, international, longitudinal
registry of patients newly diagnosed with AF at risk of
Patients with paroxysmal, persistent 
or permanent AF
Determine stroke / thromboembolic 
risk
Anticoagulation with warfarin Consider anticoagulation or aspirin
Aspirin 75–300 mg/day if no 
contraindications
Reassess risk stratification 
whenever individual risk factors are 
reviewed
Warfarin, target INR 2.5 (range 2.0–
3.0)
High Risk
Previous ischaemic stroke / TIA 
or thromboembolic event
Age   75 with hypertension,  
diabetes or vascular disease
Clinical evidence of valve 
disease, heart failure, or 
impaired LV function on 
echocardiography
Moderate Risk
Age   65 with no high risk  
factors
Age <75 with hypertension, 
diabetes or vascular disease
Low Risk
Age <65 with no moderate 
or high risk factors
Contraindications to warfarin? YES
NO
Figure 1 NICE stroke risk stratification and thromboprophylaxis algorithm [15]. Reproduced with permission.
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and clinical outcomes. The global study aims to recruit
55,000 patients in five sequential cohorts of 10,000 pa-
tients each, alongside a validation cohort of 5000 patients.
The methods for the global study have been published
[19]. The UK is the only country undertaking GARFIELD
to have its own protocol; the UK protocol was developed
from the global protocol and adapted to the UK context
to maximise the value of GARFIELD to the UK. It there-
fore has a slightly different design and includes important
and original specific research questions relevant to the UK
population. Tailoring the protocol to the UK allowed it to
be adopted by the Primary Care Research Network portfo-
lio of research. A number of publications will emanate
from the UK-specific data over the course of the study to
provide real-life contemporary evidence. As such, this
paper is an important point of reference for the UK study.
Principally, the UK study will review the management of
AF in the UK and evaluate clinical practice against guide-
line recommendations.Methods/design
Study design
GARFIELD in the UK is primary care based and aims to
recruit 4,582 patients at more than 100 sites across the
UK. Enrolment will take place in five independent se-
quential cohorts, parallel to the global study. Similar to
the global study, Cohort 1 will include a retrospective
validation cohort of patients diagnosed with AF between
6 months and 24 months previously. Data will be
extracted through a case notes review at baseline, and at
every 4 months until 24 months after diagnosis. The
data will be collected using an electronic case report
form (eCRF). A summary of the UK study design is pro-
vided in Figure 2.
Study aims
The key aims of the GARFIELD registry are to deter-
mine the real-life treatment patterns and clinical out-
comes of newly diagnosed patients with non-valvular AF
with at least one additional risk factor for stroke.
Record on screening log
Book in consent visit and consentpatient
Add follow-up events and follow-up records at 
4-month intervals until patient completes 
study 24 monthsafter diagnosis
Document on screening log
Patient interested 
in participating?
YES NO
GP surgery – identify eligible patient
Provide with invitation letter and information
sheet
 patient
Enrol patient in database
Record on enrolment sheet and update 
screening log
File consent form in site file
Fill in baseline data on eCRF
-up events and fo low-up records at 
i l il i l
 after diagnosis
 i t r st  
– identify el gible patient 
Figure 2 Summary of UK study design.
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assess the rate of stroke and systemic embolisation, and
assess the outcome of these events with specific refer-
ence to:
 The incidence and characteristics of bleeding
complications (e.g. location and severity, classified as
major, clinically relevant non-major, and minor);
 Therapy persistence, including discontinuation,
interruption, and changes of therapy regimen;
 For patients on VKAs, fluctuations in the INR over
time.
The UK protocol has additional objectives that will in-
form the management on AF. GARFIELD in the UK
seeks to evaluate the performance of the novel stroke
risk score CHA2DS2-VASc in comparison with CHADS2
in predicting stroke risk in the UK study population.
Likewise it will evaluate the effectiveness of the bleeding
risk score HAS-BLED in predicting bleeding risk within
the UK study population. In addition, the study will de-
termine the clinician and patient factors associated with
the decision to anticoagulate patients. Another unique
objective of the UK study is to determine any variations
in levels of anticoagulation associated with ethnicity.
Furthermore, the study will determine where patients
are principally diagnosed with AF and assess the role of
primary care in the management of AF in the UK.Study setting
In the UK, all healthcare delivery is centred on the gen-
eral practitioner (GP), with referrals for specialists and
for routine admission to hospital organized at the GP
level. As a result of the National Health Service struc-
ture, GPs maintain in their surgeries a complete medical
history of their patients. Recruiting from the general
practices will therefore capture all patients diagnosed
with AF regardless of their care settings, and in the UK,
these include hospital departments (cardiology) and
emergency settings. The UK is therefore recruiting solely
from the primary care setting; nevertheless, we expect to
achieve a representative sample of patients with AF be-
ing cared for in the UK, comparable to the sample
recruited in the global study.
Investigator sites (GP practices) will be representative
of the UK, and will include sites in England, Wales,
Scotland, and Northern Ireland, with the aim of achiev-
ing a sample representative of the geographical distribu-
tion of the UK population. Practices will be recruited
and trained in collaboration with national research net-
works. The Primary Care Research Network (PCRN)
England provides a world-class infrastructure to conduct
clinical research in primary care settings in the NHS by
supporting and facilitating recruitment and set up of
sites. PCRN England is delivered through eight local re-
search networks that cover the whole of England. Similar
networks operate in Scotland (Scottish PCRN), Northern
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and Wales (National Institute for Social Care and Health
Research). Expressions of interest will be sent to prac-
tices by the research network for each region, and sites
will be selected from the responses received.
Registry population
The details of the registry population are given in full in
the global GARFIELD methods paper [19].
Prospective cohorts
The eligibility criteria for the prospective cohorts are:
patients aged 18 years or older with a diagnosis of non-
valvular AF within the past 6 weeks and at least one
additional risk factor for stroke [19].
Retrospective cohort
The eligibility criteria for the retrospective cohort are:
patients with a diagnosis of non-valvular AF within the
6–24 months before enrolment, and at least one add-
itional risk factor for stroke [19].
Patient recruitment
Each participating GP will identify eligible patients using
a search of the computerised clinical record and will in-
vite them by standard letter to be enrolled in the GAR-
FIELD registry. GPs will also opportunistically inform
patients in the practice and give them a participant invi-
tation letter and information sheet.
For the retrospective cohort, a practice computer
search for all patients with a current diagnosis of AF
(between 6 months and 2 years prior to inclusion) will
be undertaken. Once identified, patients will be assessed
according to the inclusion/exclusion criteria and eligible
patients invited to participate.
For the prospective cohort, a computer search will be
undertaken at least once a month at each practice to
identify newly diagnosed patients with non-valvular AF.
Once identified, the patient will be assessed according to
the inclusion/exclusion criteria. Eligible patients will be
sent a participant invitation letter and information sheet
and asked to contact the practice if they are interested
in participating. A screening log of all patients invited to
participate in the registry will be maintained at each site.
A consent visit is arranged for interested patients, after
which they are enrolled in the registry and baseline data
are completed.
Collection of baseline and follow-up data
Data collected at baseline include: demographics (e.g.
ethnicity, sex, date of birth); body mass index; vital signs
at diagnosis; AF symptoms; type of AF (new, paroxysmal,
persistent, permanent); method and site of diagnosis;
treatment strategy initiated at diagnosis; antithrombotictherapy; treatment decision (patient and physician fac-
tors); and medical history (cardiovascular, medical,
bleeding).
Follow-up data include clinical events (stroke/TIA,
peripheral embolism, acute coronary syndrome) and out-
come of event; AF-related medical consultation and/or
hospitalisation and outcome; AF treatment change;
change in antithrombotic therapy (discontinuation, dur-
ation on therapy, reasons for discontinuation); bleeding
events (classified as major, clinical relevant non-major,
and minor); bleeding location of treatment (e.g. Accident
and Emergency, GP practice); outcome of bleeding (re-
covered, permanently disabled, fatal); bleeding healthcare
utilisation (hospitalisation, Accident and Emergency,
physician, etc.); medical history update; mortality, in-
cluding sudden cardiac death and non-cardiovascular
death; and INR records in relation to therapeutic range,
and location of INR monitoring.
Clinical outcomes and data quality
The study outcomes comprise clinical events (stroke,
TIA, systemic and pulmonary embolism, myocardial in-
farction), bleeding events, therapy persistence, hospital
visits and INR monitoring, and are listed in below:
 Cerebrovascular events defined as stroke including:
– Primary ischaemic stroke
– Primary intracerebral haemorrhage
– Secondary haemorrhagic ischaemic stroke
 TIAs
 Systemic embolism
 Pulmonary embolism
 Mortality
 Acute coronary syndromes including:
– Unstable angina
– ST-elevation myocardial infarction
– Non-ST-elevation myocardial infarction
 Bleeding events including:
– Frequency
– Location
– Severity (classified as major [clinically overt
bleeding associated with a fall in haemoglobin of
≥2 g/dl OR a transfusion of ≥2 packed red blood
cells or whole blood OR a critical site:
intracranial, intraspinal, intraocular, pericardial,
intra-articular, intramuscular with compartment
syndrome, retroperitoneal OR a fatal outcome],
clinical relevant non-major and minor)
 Therapy persistence, including:
– Rate of discontinuation
– Duration of time on therapy
– Reasons for discontinuation
– Duration and cause of treatment interruption or
suspension
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hospitalisation and outcomes
 Any other hospital visits (inpatient, outpatient,
emergency department)
 Major adverse cardiac events
 For patients treated with VKA:
– Frequency and timing of monitoring required in
maintaining therapeutic anticoagulation
– INR recordings in relation to therapeutic range
– Location of INR monitoring and medical
consultations due to INR testing
– Use of bridging anticoagulation necessitated by
VKA interruption
– Outcomes in relation to INR fluctuation.
Source data verification will be undertaken in 20% of
all cases to verify adherence to the protocol and assess
the level and accuracy of data recording.
Funding
The GARFIELD Registry is sponsored by the Throm-
bosis Research Institute, London, UK. Funding of the
registry is provided through an educational research
grant from Bayer Pharma AG, Berlin, Germany.
Sample size and data analysis
The total projected sample size for the UK is 4,582, com-
prising 417 retrospective patients for Cohort 1 and 833 pro-
spective patients for Cohorts 1 to 5. With these projected
sample sizes the precision of estimated incidence of stroke
is set out in Table 1 for different levels of incidence.
An interim analysis will be done at the UK level for
the baseline data in each cohort and after all patients inTable 1 Precision of estimated incidence of stroke for
different levels of incidence, and confidence intervals on
effect sizes for quantitative measures
Width of 95% confidence interval
Expected
incidence of
stroke
Sample size of
retrospective
patients: 417
Cohort size of
prospective
patients: 833
Total
sample size
of 4,582
2.5% ±1.5% ±1.1% ±0.5%
5% ±2.1% ±1.5% ±0.6%
10% ±2.9% ±2.0% ±0.9%
20% ±3.8% ±2.7% ±1.2%
30% ±4.4% ±3.1% ±1.3%
40% ±4.7% ±3.3% ±1.4%
50% ±4.8% ±3.4% ±1.4%
Width of 95% confidence interval
Sample size of
retrospective
patients: 417
Cohort size of
prospective
patients: 833
Total sample
size of 4,582
0.14 0.10 0.04each of the first four cohorts have completed the study.
For a full analysis, baseline data, follow-up data, and
study endpoint data will be summarised overall and by
treatment groups, cohort, and region. Summaries of cat-
egorical data will be presented as frequency counts, per-
centages, and 95% confidence intervals. Continuous data
will be presented as means (standard deviations), me-
dians (with 95% confidence intervals), interquartile
ranges, minimum, maximum, and number of patients.
Comparison of follow-up and outcome data between
treatment groups, cohorts, and regions will be made using
linear (for continuous outcomes) or non-linear (for cat-
egorical outcomes) mixed modelling with practice in-
cluded as a random effect. Association between outcome
variables and baseline data will be explored using the same
method. For continuous data, normality of residuals will
be tested using the Kolmogorov–Smirnov test and trans-
formation or bootstrapping will be implemented where re-
quired. Time-to-event analysis will use Kaplan–Meier and
Cox regression analyses to summarise and explore the as-
sociation with baseline and other pertinent data. Compari-
son of CHADS2, CHA2DS2VASc, and HAS-BLED risk
measures will be compared on the basis of receiver-
operating characteristic curve analyses. The baseline char-
acteristics of the patients – who have been classified as at
risk of stroke according to physician-perceived risk factors
or combinations of factors – will be reported.
Discussion
The development of this large, ongoing registry allows
the opportunity to answer several research questions
that have not previously been investigated within a non-
randomised, non-selected population. These questions
will pertain to:
 Clinical risks within a non-selected population of
newly diagnosed patients with AF, compared with
data from randomised trials in which prevalent,
stable VKA users were preferably enrolled [20];
 Risks and benefits associated with oral
anticoagulation;
 Quality of INR control in everyday clinical practice;
 Persisting barriers to prescribing oral
anticoagulation;
 The economic burden of AF;
 The main diagnostic pathways, including the real-
life identification and management of patients at
various levels of risk for ischaemic stroke.
GARFIELD UK data will provide a comprehensive de-
scription of AF management and insights into the ra-
tionale for decisions relating to anticoagulation. The
findings will establish how well the NICE guidelines have
been implemented in the UK. Whilst NICE guidelines
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nationally recognised to reflect best practice. Further,
GARFIELD will inform on the effectiveness of the NICE
treatment guidelines and allow an evaluation of such
guidelines and patient outcomes.
The global data will provide comparable information
within which to consider national data and models of
best practice, and the significance of the context in
interpreting findings. The range of data will also provide
evaluation of any inequalities in the UK in terms of AF
diagnosis, management, and possibly clinical outcomes.
The study will provide the opportunity to identify differ-
ences in management and outcomes across care settings,
and will offer clarity relating to the effectiveness of INR
control within the various test settings in the UK, as well
as the effectiveness of the recent stroke (CHA2DS2VASc)
and bleeding (HAS-BLED) risk scores.
The study will provide real-world prospective data that
will allow an evaluation of clinical practices and related
outcomes in the VKA-only era, but will also report on
outcomes relating to any novel anticoagulants or new
therapies licensed for use in the UK during the duration
of the study.
Appendix
UK GARFIELD Investigators
David A Fitzmaurice at the University of Birmingham
and the UK Clinical Research Network (Primary Care).
Will Murdoch, Naresh Chaunan, Daryl Goodwin,
Richard McManus, Ramila Patel, Philip Saunders,
Bennett Wong, Richard Evans, Philip Saunders, Janet
Leese, Prem Jhittay, Andrew Ross, Manjit Kainth, Kevin
Douglas, Gill Pickavance, Joanna McDonnell, Andrea
Williams, Trevor Gooding, Helga Wagner, Geert Van
Zon, Kevin Jones, Shoeb Suryani, Matt Thomas, Emily
Watson, Arun Singal, William Wilcock, Subharsi Sircar,
John Cairns, Drew Gilliland, Roman Bilas, Elizabeth
Strieder, Peter Hutchinson, Anne Wakeman, Michael
Stokes, Alistair Howitt, Bhaskhar Vishwanathan, Nigel
Bird, Dominic Gray, Paul Evans, Matt Clark, John Bisatt,
Jennifer Litchfield, Elizabeth Fisher, Tim Fooks, Richard
Kelsall, Neil Paul, Elizabeth Alborough, Michael Aziz,
Cobarsanellore Ramesh, Peter Wilson, Simon Franklin,
Sue Fairhead, Julian Thompson, Vivien Joseph, Gary
Taylor, Huw Charles, Dawn Tragen, Wendy Molefi-
Youri, David Seamark, Carolyn Paul, Mark Richardson,
Angus Jefferies, Helen Sharp, Hywel Jones, Claire Giles,
Michael Page, Olaleye Oginni, Jehad Aldegather, Simon
Wetherell, William Lumb, Phil Evans, Frances Scouller,
Neil Macey, Stephen Rogers, Yvette Stipp, Richard West,
Stephen Thurston, Paul Wadeson, John Matthews, Preeti
Pandya, Andrew Gallagher, Raj Priyadharshan, Jayne
Oliver, Tammy Railton, Emyr Davies, Steven Sayers,
Claire Hutton, Nick Walls, Richard Thompson, BijoySinha, Keith Butter, Susan Barrow, Helen Little, David
Russell, Jason Davies, Ikram Haq, Paul Ainsworth, Claire
Jones, Phil Weeks, Jane Eden, David Kernick, Janet
Glencross, Alison MacLeod, Karen Poland, Connor
Mulholland, Alison Warke, Paul Conn, Gerry Burns,
Richard Smith, Simon Lowe, Rakee Kamath.
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AF: Atrial fibrillation; CHA2DS2-VASc: Cardiac failure, Hypertension, Age ≥75
[Doubled], Diabetes, Stroke [Doubled] – Vascular disease, Age 65–74 and Sex
category [Female]); CHA2DS2-VASc: Cardiac failure, Hypertension, Age ≥75
[Doubled], Diabetes, Stroke [Doubled] – Vascular disease, Age 65–74 and Sex
category [Female]; CHADS2: Cardiac failure, Hypertension, Age, Diabetes,
Stroke (Doubled); GARFIELD: Global Anticoagulant Registry in the FIELD;
GP: General practitioner; HAS-BLED: Hypertension, Abnormal renal/liver
function (1 point each), Stroke, Bleeding history or predisposition, Labile INR,
Elderly (>65), Drugs/alcohol concomitantly (1 point each); INR: International
normalised ratio; TIA: Transient ischaemic attack.
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